Strykagen Business Model

• Dedicated to developing therapies, diagnostics and biomarkers for muscular dystrophy

• Development of life changing therapeutics for rare muscle diseases

• Established scientific team with expertise in muscular dystrophy translational research

• Partnerships with academic institutions

• Relationships with patient advocacy groups

Strykagen Pipeline

• Exclusive market for products through orphan drug status

• Robust product pipeline for the muscular dystrophies

• Prolonged product lifespan for rare muscle diseases

• Extended product application for aging, cachexia and sports injuries